EGFR and neoplasm: In the anti-EGFR-GN+NIR-PTT group, the PA signal amplitude and bioluminescence activity of tumors remarkably decreased after second and third treatments, which may selectively reflect EGFR-positive tumor cell damage or tumor vascular insult.